← FDA DRUG APPROVALS

FDA ANDA · ANDA211592

VIGABATRIN

Sponsor: INVAGEN PHARMS

APPLICATION
ANDA211592
TYPE
ANDA
ORIGINAL APPROVAL
2019-12-03
LATEST ACTION
2026-03-18
ROUTE
ORAL
DOSAGE FORM
FOR SOLUTION
MARKETING STATUS
Prescription

Products

VIGABATRINPrescription
VIGABATRIN 500MG/PACKET · FOR SOLUTION · ORAL

Approval history

2026-03-18REMS · Supplement 10AP
2024-09-12REMS · Supplement 9AP
2022-10-28Labeling · Supplement 5 · standardAP
2022-10-28Labeling · Supplement 3 · standardAP
2022-10-12REMS · Supplement 6AP
2020-10-02REMS · Supplement 4AP
2020-04-17REMS · Supplement 2AP
2019-12-03UNKNOWN · Original · standardREMSAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →